Brief: Sino Biopharmaceutical Says Application For Phase II Clinical Trial On LM-24C5 "CEACAM5/4-1BB Bispecific Antibody" Approved By China NMPA
07/08/2025 14:45
Aug 7 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY CHINA NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up